854745-35-0Relevant articles and documents
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
Randolph, John T.,Huang, Peggy P.,Flosi, William J.,DeGoey, David,Klein, Larry L.,Yeung, Clinton M.,Flentge, Charles,Sun, Mingua,Zhao, Chen,Dekhtyar, Tatyana,Mo, Hongmei,Colletti, Lynn,Kati, Warren,Marsh, Kennan C.,Molla, Akhteruzzaman,Kempf, Dale J.
, p. 4035 - 4046 (2006)
As a continuation of the recently communicated discovery of oximinoarylsulfonamides as potent inhibitors of HIV-1 aspartyl protease, compounds bearing pyridylmethyl substituents at P3 were designed and synthesized. Potent analogs in this series provided low single-digit nanomolar EC50 values against both wild-type HIV and resistant mutant virus (A17), attenuated some 3- to 12-fold in the presence of 50% human serum. Pharmacokinetic results for compounds in this series showed good to excellent exposure when co-administered orally with an equal amount of ritonavir (5 mg/kg each) in the rat, with average AUC >8 μg h/mL. Similar dosing in dog resulted in significantly lower plasma levels (average AUC i = 2.4 nM).
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
Ghosh, Arun K.,Sridhar, Perali Ramu,Leshchenko, Sofiya,Hussain, Azhar K.,Li, Jianfeng,Kovalevsky, Andrey Yu.,Walters, D. Eric,Wedekind, Joseph E.,Grum-Tokars, Valerie,Das, Debananda,Koh, Yasuhiro,Maeda, Kenji,Gatanaga, Hiroyuki,Weber, Irene T.,Mitsuya, Hiroaki
, p. 5252 - 5261 (2008/02/11)
Structure-based design and synthesis of novel HIV protease inhibitors are described. The inhibitors are designed specifically to interact with the backbone of HIV protease active site to combat drug resistance. Inhibitor 3 has exhibited exceedingly potent enzyme inhibitory and antiviral potency. Furthermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a variety of multi-PI-resistant clinical strains. The inhibitors incorporated a stereochemically defined 5-hexahydrocyclopenta[b] furanyl urethane as the P2-ligand into the (R)-(hydroxyethylamino)sulfonamide isostere. Optically active (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[e]furan was prepared by an enzymatic asymmetrization of meso-diacetate with acetyl cholinesterase, radical cyclization, and Lewis acid-catalyzed anomeric reduction as the key steps. A protein-ligand X-ray crystal structure of inhibitor 3-bound HIV-1 protease (1.35 ? resolution) revealed extensive interactions in the HIV protease active site including strong hydrogen bonding interactions with the backbone. This design strategy may lead to novel inhibitors that can combat drug resistance.
